← All trials
NCT05817240
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 3, 2023
- Primary completion
- Jun 11, 2023
- Completion date
- Jun 21, 2023
- First posted
- Apr 18, 2023
- Last posted
- Dec 15, 2023
- Enrollment
- 21
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Endeavor Biomedicines, Inc.Lead sponsor
- Endeavor BiomedicinesStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.